Low-grade non-Hodgin's lymphoma (NHL) is sensitive to a wide variety of treatments, including radiation, single-agent alkylating therapy, combination chemotherapy and interferons. Although tumour responses are common even in recurrent disease, low-grade NHL follows a chronic relapsing pattern of disease. The majority of patients die from their disee, with a median survival of 6-10 years (Horning, 1994) . There is therefore a continuing need for novel treatments for low-grade NHL. Temozolomide is an imidamtetrazine derivative with broad-spectrum anti-tumour activity in experimental models (Stevens et al., 1987; Stevens and Newlands, 1993) . It is an analogue of mitozolomide with less toxicity in precinical studies, but myelosuppression remains dose limiting (Newlands et al., 1992) . It has excellent oral bioavailability. In preclinical stdies, its activity was schedule dependent. In phase I and II studies it has shown promising actity against metastatic melanoma and primary brain tumours when adminitered daily for five consecutive days every 4 weeks (Newlands et al., 1992; O'Reilly et al., 1993) . Responses were also obtained in two patients with mycosis fungoides. We therefore tested temozolomide for activity in low-grade NHL using the 5 day schdule. radiotherapy and five with a biological agent. All had recived prior chemotherapy, with a median (range) of three (1-7) regm. All the patents with lymph node involvement, two were bone marrow positive, three had lung meta- 
